<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200782</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2017-00689</org_study_id>
    <nct_id>NCT03200782</nct_id>
  </id_info>
  <brief_title>Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study</brief_title>
  <acronym>Hypo-BEAR</acronym>
  <official_title>Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate whether hypoglycaemia observed after food intake
      in bariatric patients can be either influenced by an SGLT2 inhibitor, empagliflozin, or via
      inhibition of inflammation with an human interleukin-1 receptor antagonist (IL1-RA,
      anakinra).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postprandial hypoglycemia also referred as late-dumping after bariatric surgery can be
      clinically asymptomatic but also life-threatening. The exact mechanisms leading to
      postprandial hypoglycemia are not fully understood and therapeutic options are limited and
      often accompanied with reduced life-quality and weight gain.

      In this study, prospective, randomly selected and double-blinded treatment is performed to
      investigate the effect on postprandial hypoglycemia. A total of 12 subjects participate in
      the study. After a screening date, three study dates will be performed. Participation in the
      study usually takes two weeks, but can also be extended to three weeks in individual cases.
      The University Hospital Basel will be the only test center in this study.

      In order to check whether the increase in blood glucose after food intake and subsequent
      excessive reaction of the body followed by hypoglycaemia patients receive either anakinra as
      a subcutaneous injection 3h or empagliflozin as a tablet 2 h before a liquid standardized
      test meal. On one study day only subcutaneous and oral placebo control will be used.

      At the beginning of each study date as well as at the time of the test meal several blood
      samples will be taken to evaluate blood glucose and blood glucose-influencing parameters
      (insulin / C-peptide, intestinal hormones, inflammatory parameters such as C-reactive
      protein, IL1beta and IL1-receptor agonist as well as macrophage and t-lymphocyte
      subpopulations) will be controlled. Questionnaires for dumping symptoms (Dumping Rating
      scale, Sigstad Score) and hypoglycemia testing with mini-mental test, stanford sleepiness
      scale and Edinburgh Hypoglycemia Scale will be performed repetitively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">July 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial hypoglycemia in patients after bariatric surgery</measure>
    <time_frame>6 hours</time_frame>
    <description>To assess whether empagliflozin or anakinra compared to placebo reduce the severity of hypoglycemia (i.e. change of blood glucose level in mmol/l) following a mixed-meal in patients after bariatric surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of C-peptide</measure>
    <time_frame>6 hours</time_frame>
    <description>plasma level of c-peptide with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma level of IL-1Beta</measure>
    <time_frame>6 hours</time_frame>
    <description>plasma level of IL-1Beta with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma level of GLP1</measure>
    <time_frame>6 hours</time_frame>
    <description>plasma level of GLP1 with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of glucagon level</measure>
    <time_frame>6 hours</time_frame>
    <description>plasma level of glucagon with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Edinburgh Hypoglycemia Scale</measure>
    <time_frame>6 hours</time_frame>
    <description>changes in Edinburgh Hypoglycemia Scale with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of glucose needed for restoring normoglycemia</measure>
    <time_frame>6 hours</time_frame>
    <description>amount (gramm) of glucose needed for restoring normoglycemia with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of time needed for restoring normoglycemia</measure>
    <time_frame>6 hours</time_frame>
    <description>length of time (min) needed for restoring normoglycemia with anakinra or empagliflozin in comparison to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Postprandial Hypoglycemia</condition>
  <condition>Bariatric Surgery</condition>
  <condition>Late Dumping Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Drug A Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational Drug B Anakinra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response</description>
    <arm_group_label>Investigational Drug A Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level</description>
    <arm_group_label>Investigational Drug B Anakinra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>oral placebo (winthrop tablet)</intervention_name>
    <description>subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient</description>
    <arm_group_label>Placebo-Placebo</arm_group_label>
    <arm_group_label>Investigational Drug B Anakinra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>subcutaneous placebo (0.67 ml of 0.9% sodium chloride)</intervention_name>
    <description>subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'</description>
    <arm_group_label>Placebo-Placebo</arm_group_label>
    <arm_group_label>Investigational Drug A Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients after bariatric operation (i. e. sleeve gastrectomy, roux-y-gastric bypass)
             with documented hypoglycemia, i. e. â‰¤ 2.5 mmol/l and hypoglycaemic symptoms.

          -  For subjects with reproductive potential, willingness to use contraceptive measures
             adequate to prevent the subject or the subject's partner from becoming pregnant during
             the study

        Exclusion Criteria:

          -  Signs of current infection

          -  Use of any investigational drug in the last four weeks prior to enrolment

          -  Use of any anti-diabetic drugs

          -  adrenal insufficiency and/or substitution with glucocorticoids

          -  Neutropenia (leukocyte count &lt; 1.5 Ã— 109/L or absolute neutrophil count (ANC) &lt; 0.5 Ã—
             109/L)

          -  Anemia (hemoglobin &lt; 11 g/dL for males, &lt; 10 g/dL for females)

          -  Clinically significant kidney or liver disease (creatinine &gt; 1.5 mg/dL, aspartate
             aminotransferase (AST)/alanin aminotransferase (ALT) &gt; 2 Ã— ULN, alkaline phosphatase &gt;
             2 Ã— ULN, or total bilirubin [tBili] &gt; 1.5 Ã— ULN)

          -  Current immunosuppressive treatment or documented immunodeficiency

          -  Uncontrolled congestive heart failure

          -  Uncontrolled malignant disease

          -  Currently pregnant or breastfeeding

          -  known lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Donath, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hopsital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Hepprich, MD</last_name>
    <phone>0041613286077</phone>
    <email>matthias.hepprich@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Donath, MD, Prof.</last_name>
    <phone>0041612652525</phone>
    <email>marc.donath@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>Basel</city>
        <zip>4056 Basel</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Y. Donath, Professor</last_name>
      <phone>+41 61 265 50 78</phone>
      <email>marc.donath@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postprandial hypoglycemia</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>late dumping syndrome</keyword>
  <keyword>anakinra</keyword>
  <keyword>empagliflozin</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <keyword>IL-1Beta</keyword>
  <keyword>IL1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Dumping Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

